News
ENGN
1.720
-8.99%
-0.170
Weekly Report: what happened at ENGN last week (1109-1113)?
Weekly Report · 2d ago
enGene: Downgrading To 'Sell' On Non-Competitive Efficacy Detalimogene For NMIBC
Seeking Alpha · 4d ago
Leerink Partners Upgrades enGene Therapeutics to Outperform from Market Perform
NASDAQ · 4d ago
Leerink upgrades enGene to Outperform as worst-case scenario off the table
TipRanks · 5d ago
enGene Holdings (ENGN) Receives a Hold from Guggenheim
TipRanks · 5d ago
enGene Therapeutics Price Target Announced at $5.00/Share by Leerink Partners
Dow Jones · 5d ago
enGene Therapeutics Raised to Outperform From Market Perform by Leerink Partners
Dow Jones · 5d ago
Leerink Partners Upgrades enGene Therapeutics to Outperform, Announces $5 Price Target
Benzinga · 5d ago
enGene upgraded to Outperform from Market Perform at Leerink
TipRanks · 5d ago
Biotech Stocks Rally: ADXN Soars 71%, ENGN Jumps 26%, NTHI Gains 12%, PRQR Rises 10%
NASDAQ · 5d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 5d ago
enGene rises after mid-stage trial data for bladder cancer therapy; Piper upgrades
Seeking Alpha · 5d ago
This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Benzinga · 6d ago
enGene Therapeutics Raised to Overweight From Neutral by Piper Sandler
Dow Jones · 6d ago
enGene Therapeutics Price Target Maintained With a $4.00/Share by Piper Sandler
Dow Jones · 6d ago
Piper Sandler Upgrades enGene Therapeutics to Overweight, Maintains Price Target to $4
Benzinga · 6d ago
enGene Announces LEGEND Trial Results and FDA Alignment
TipRanks · 6d ago
enGene Therapeutics Price Target Raised to $6.00/Share From $2.00 by Wells Fargo
Dow Jones · 6d ago
enGene Therapeutics Raised to Overweight From Equal-Weight by Wells Fargo
Dow Jones · 6d ago
Analysts’ Top Healthcare Picks: enGene Holdings (ENGN), Janux Therapeutics Inc (JANX)
TipRanks · 6d ago
More
Webull provides a variety of real-time ENGN stock news. You can receive the latest news about enGene Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENGN
enGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs. The Company's lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene at high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene is being developed using its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).